Rare diseases
Investigational molecules
Locations
85 Wells Avenue, 02459-3298, United States
Clinical research in myelofibrosis includes both JAK inhibitor-naïve and previously treated populations, with attention to moderate thrombocytopenia and treatment-naïve disease. The sponsor also studies combinations involving ruxolitinib in this hematologic setting.
The research focus centers on disease control in chronic marrow-related disorders and symptom burden associated with myelofibrosis.
Karyopharm Therapeutics Inc. runs clinical trials in conditions such as Myelofibrosis, Plasma cell myeloma, Plasma cell myeloma refractory, Thrombocytopenia, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Greece
Belgium
ItalyBelgiumBelgiumItalyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
